These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 35154513)
1. Prognosis Risk Model Based on Pyroptosis-Related lncRNAs for Bladder Cancer. Lu Z; Tang F; Li Z; Lai Y; Lu Z; Zhang J; Tang Z; Cai W; He Z Dis Markers; 2022; 2022():7931393. PubMed ID: 35154513 [TBL] [Abstract][Full Text] [Related]
2. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Lu H; Wu J; Liang L; Wang X; Cai H Front Immunol; 2022; 13():803355. PubMed ID: 35154117 [TBL] [Abstract][Full Text] [Related]
3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
4. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer. Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694 [TBL] [Abstract][Full Text] [Related]
5. A pyroptosis-related lncRNA signature in bladder cancer. Wang P; Wang Z; Zhu L; Sun Y; Castellano L; Stebbing J; Yu Z; Peng L Cancer Med; 2023 Mar; 12(5):6348-6364. PubMed ID: 36237132 [TBL] [Abstract][Full Text] [Related]
6. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma. Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955 [TBL] [Abstract][Full Text] [Related]
7. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer. Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227 [TBL] [Abstract][Full Text] [Related]
8. Development and validation of pyroptosis-related lncRNAs prediction model for bladder cancer. Lia T; Shao Y; Regmi P; Li X Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 35024796 [TBL] [Abstract][Full Text] [Related]
9. Identification of a pyroptosis-associated long non-coding RNA signature for predicting the immune status and prognosis in skin cutaneous melanoma. Wu L; Liu G; He YW; Chen R; Wu ZY Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5597-5609. PubMed ID: 34604952 [TBL] [Abstract][Full Text] [Related]
10. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma. Zhu W; Ye Z; Chen L; Liang H; Cai Q Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154 [TBL] [Abstract][Full Text] [Related]
11. Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma. Wang P; Wang Z; Lin Y; Castellano L; Stebbing J; Zhu L; Peng L Mol Biotechnol; 2024 Feb; 66(2):332-353. PubMed ID: 37154865 [TBL] [Abstract][Full Text] [Related]
12. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs. Xu C; Chen A; Mao C; Cui B Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097 [TBL] [Abstract][Full Text] [Related]
13. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer. Peng Y; Wang H; Huang Q; Wu J; Zhang M J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063 [TBL] [Abstract][Full Text] [Related]
14. A novel molecular subtypes and risk model based on inflammatory response-related lncrnas for bladder cancer. Tang F; Zhang J; Lu Z; Liao H; Hu C; Mai Y; Lai Y; Lu Z; Tang Z; Li Z; He Z Hereditas; 2022 Aug; 159(1):32. PubMed ID: 35964079 [TBL] [Abstract][Full Text] [Related]
15. Identification of a pyroptosis-related lncRNA risk model for predicting prognosis and immune response in colon adenocarcinoma. Tan Y; Lu L; Liang X; Chen Y World J Surg Oncol; 2022 Apr; 20(1):118. PubMed ID: 35413978 [TBL] [Abstract][Full Text] [Related]
16. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients. Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697 [TBL] [Abstract][Full Text] [Related]
17. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Li L; Xie R; Lu G Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555 [TBL] [Abstract][Full Text] [Related]
18. Construction and Validation of Pyroptosis-Related lncRNA Prediction Model for Colon Adenocarcinoma and Immune Infiltration Analysis. Liu Q; Chen N; Liu L; Zheng Q; Liao W; Zhao M; Zeng J; Tang J Dis Markers; 2022; 2022():4492608. PubMed ID: 36168326 [TBL] [Abstract][Full Text] [Related]
19. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer. Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610 [TBL] [Abstract][Full Text] [Related]
20. Identification of pyroptosis-related lncRNA subtype and signature predicts the prognosis in bladder cancer. Zeng T; Ye J; Wang H; Tian W Medicine (Baltimore); 2023 Oct; 102(42):e35195. PubMed ID: 37861525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]